GIVAT SHMUEL, Israel--(BUSINESS WIRE)--Jan. 18, 2006--Gammacan International (OTC BB:GCAN), a developer of immunotherapies for cancer and other diseases, today announced that the Company has consummated two private placements aggregating $1.2 million. These investments follow the recently announced (Nov. 15, 2005) initial investment of $500,000.00 by Sal. Oppenheimer Jr. & Cie. (Switzerland) Ltd. out of a potential $2.5 million aggregate investment.
